AMSTERDAM – Bristol-Myers Squibb Co.'s lead nonalcoholic steatohepatitis (NASH) candidate, BMS-986036, significantly reduced liver fat vs. placebo, meeting the primary endpoint of a phase II trial, the company reported during the International Liver Conference.